Background and Objectives: Red cell type RhDVa lacks epD1 and 5 and is encoded by hybrid RHD–CE(5)–D alleles. We analyzed RhDVa and RhDVa–like samples in Japanese blood donors. Materials and Methods: Ten RhDVa samples lacked epD1 and 5 and 3 RhDVa–like variants also lacked, epD2 and a part of 6/7. We identified the full–length nucleotide sequences of the complementary DNA (cDNA) synthesized from 4 samples: 3 of type DVa and the 4th a DVa–like variant. Results: Although their sequences differed from each other, all the substitutions were exclusively in exon 5. Three DVa samples had hybrid RHD–CE(5)–D alleles, but the DVa–like variant had a unique nucleotide substitution with a single amino acid change, E233K. Exon 5 of the genomic DNA from all 13 samples was analyzed by sequencing. No other sequences were identified. Conclusion: All RhDVa and RhDVa–like variants had the substitution for E233. E233 seems to be a determinant of epD1 and 5. A new category of RhD variant, DYO, was identified.

1.
Daniels G: Rh blood group systems; in Human Blood Groups. Oxford, Blackwell Science, 1995, pp 257–355.
2.
Jones J, Scott ML, Voak D: Monoclonal anti–D specificity and RhD structure: Criteria for selection of monoclonal anti–D reagents for routine typing of patients and donors. Transfus Med 1995;5:171–184.
3.
Jones J: Identification of two new D variants, DHMi and DHMii using monoclonal anti–D. Vox Sang 1995;69:236–241.
4.
Avent ND, Jones JW, Liu W, Scott ML, Voak D, Flegel WA, Wagner FF, Green C: Molecular basis of the D variant phenotypes DNU and DII allows localization of critical amino acids required for expression of RhD epitopes epD3, 4 and 9 to the sixth external domain of the RhD Protein. Br J Haematol 1997;97:366–371.
5.
Jones JW, Finning K, Mattock R, Williams M, Voak D, Scott ML, Avent ND: The serological profile and molecular basis of a new partial D phenotype, DHR. Vox Sang 1997;73:252–256.
6.
Mouro I, Le van Kim C, Rouillac C, van Rhenen DJ, Le Pennec PY, Bailly P, Cartron JP, Colin Y: Rearrangements of the blood group RhD gene associated with the DVI category phenotype. Blood 1994;83:1129–1135.
7.
Rouillac C, Le van Kim C, Blancher A, Roubinet F, Cartron JP, Colin Y: Lack of G blood group antigen in DIIIb erythrocytes is associated with segmental DNA exchange between RH genes. Br J Haematol 1995;89:424–426.
8.
Rouillac C, Colin Y, Hughes–Jones NC, Beolet M, D’Ambrosio AM, Cartron JP, Le van Kim C: Transcript analysis of D category phenotypes predicts hybrid RhD–CE–D proteins associated with alteration of D epitopes. Blood 1995;85:2937–2944.
9.
Beckers EAM, Faas BHW, Ligthart P, Simsek S, Overbeeke MAM, Kr von dem Borne AEG, van Rhenen DJ, van der Schoot CE: Characterization of the hybrid RHD gene leading to the partial D category IIIc phenotype. Transfusion 1996;36:567–574.
10.
Rouillac C, Gane P, Cartron J, Le Pennec PY, Cartron JP, Colin Y: Molecular Basis of the Altered Antigenic Expression of RhD in Weak D (Du) and RhC/e in RN Phenotypes. Blood 1996;87:4853–4861.
11.
Beckers EAM, Faas BHW, Simsek S, Overbeeke MAM, van Rhenen DJ, Wallace M, Kr von dem Borne AEG, van der Schoot CE: The genetic basis of a new partial D antigen: DDBT. Br J Haematol 1996;93:720–727.
12.
Matassi G, Chérif–Zahar B, Mouro I, Cartron JP: Characterization of the recombination hot spot involved in the genomic rearrangement leading to the hybrid D–CE–D gene in the DVI phenotype. Am J Hum Genet 1997;60:808– 817.
13.
Wagner FF, Gassner C, Müller TH, Schönitzer D, Schunter F, Flegel WA: Three molecular structures cause rhesus D category VI phenotypes with distinct immunohematologic features. Blood 1998;91:2157–2168.
14.
Avent ND, Martin PG, Armstrong–Fisher SS, Liu W, Finning KM, Maddocks D, Urbaniak SJ: Evidence of genetic diversity underlying Rh D–, weak D (Du), and partial D phenotypes as determined by multiplex polymerase chain reaction analysis of the RHD Gene. Blood 1997;89:2568–2577.
15.
Omi T, Takahashi J, Tsudo N, Okuda H, Iwamoto S, Tanaka M, Seno T, Tani Y, Kajii E: The Genomic Organization of the Partial D Category DVa: The presence of a new partial D associated with the DVa phenotype. Biochem Biophys Res Commun 1999;254:786–794.
16.
Lomas C, Tippett P, Thompson KM, Melamed MD, Huges–Jones NC: Demonstration of seven epitopes on the Rh antigen D using human monoclonal anti–D antibodies and red cells from D categories. Vox Sang 1989;57: 261–264.
17.
Apoil PA, Reid ME, Halverson G, Mouro I, Colin Y, Roubinet F, Cartron JP, Blancher A: A human monoclonal anti–D antibody which detects a nonconformation–dependent epitope on the RhD protein by immunoblot. Br J Haematol 1997;98:365–374.
18.
Bennett PR, Le Van Kim C, Colin Y, Warwick RM, Chérif–Zahar B, Fisk NM, Cartron JP: Prenatal determination of fetal RhD type by DNA amplification. N Engl J Med 1993; 329:607–610.
19.
Sekizawa A, Watanabe A, Kimura T, Saito H, Yanaihara T, Sato T: Prenatal diagnosis of the fetal RhD blood type using a single fetal nucleated erythrocyte from maternal blood. Obstet Gynecol 1996;87:501–505.
20.
Scott M: Rh Serology – coordinator’s report. Transfus Clin Biol 1996;3:333–338.
21.
Branch DR, Hian ALSS, Carlson F, Maslow WC, Petz LD: Erythrocyte age–fraction using a Percoll™–Renografin® density gradient: Application to autologous red cell antigen determinations in recently transfused patients. Am J Clin Pathol 1983;80:453–458.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.